Stepan (SCL) Q1 2025 Earnings Call Transcript

Stepan delivered first-quarter adjusted EBITDA of $57.5 million, up 12% year over year, and adjusted net income of $19.3 million, up 32%, supported by 4% consolidated volume growth across all segments. Surfactants and Specialty Products posted double-digit earnings growth, while Polymers was pressured by a 7% price decline, less favorable mix, and high-cost inventory carryover. Free cash flow was negative $25.8 million, but management still expects full-year EBITDA, earnings, and free cash flow growth as Pasadena ramps and tariff-related costs are recovered.

Analysis

The core signal here is not the headline EBITDA beat; it is the earnings inflection from mix plus self-help occurring before Pasadena is fully monetized. That creates a favorable setup for margin expansion into the back half of the year, because the new alkoxylation capacity should convert from drag to contribution just as the company captures more Tier 2/3 share and the ag distribution channel remains strong. In other words, the quarter likely understates run-rate power if demand holds and startup friction fades.

The more interesting second-order effect is competitive: tariff noise is pushing customers to reconsider sourcing and local supply chains, which should help regional players with embedded manufacturing and qualification capabilities. Stepan’s exposure is not to direct tariff cost so much as to the bidding power it gains if import competition gets less attractive in MCT and certain surfactant niches. The risk is that the same tariff uncertainty that improves competitive position also causes customers to delay project qualification and inventory decisions, which can push out the benefit by one to two quarters.

Polymers looks like the swing factor. The apparent weakness is partly transitory inventory drag, but the product mix shift toward commodity PA means revenue can grow while EBITDA lags, so the market may overestimate the sustainability of volume growth if it assumes all end markets carry similar economics. If interest rates stay elevated, rigid polyol remains capped; if they ease, this segment has the most torque to surprise positively over the next 6-12 months.

Contrarian takeaway: the market may be too focused on near-term free cash flow negativity and not enough on the sequencing of earnings. Q1 working-capital stress and tariff stockpiling are timing effects, while Pasadena, pricing catch-up, and mix improvement are structural. That asymmetry argues for looking through a weak cash quarter and positioning for a stronger second-half reset.

Key Decisions for Investors

• Go long SCL on a 3-6 month horizon; risk/reward improves if Q2 shows reduced Pasadena drag and Q3 shows first meaningful contribution. Upside case is a back-half margin step-up, while downside is limited if volume stays firm and tariff pass-through holds.
• Buy SCL Jan-2026 call spreads to express the second-half inflection with defined downside; the thesis is that full Pasadena contribution and pricing recovery are not in consensus. Use strikes roughly 10-15% above spot to avoid paying for the current quarter noise.
• Pair trade: long SCL / short a higher-beta construction-sensitive chemicals name with more levered exposure to rigid polyols and slower self-help. The idea is to isolate Pasadena and customer-diversification execution versus pure macro construction demand.
• If you already own SCL, hold through Q2 but trim only if free cash flow remains negative into Q3 without clear inventory unwind; that would signal the working-capital/tariff effect is becoming structural rather than temporary.
• Watch for a tactical add on any pullback driven by tariff headlines rather than operating data; those selloffs should be faded unless April/May order commentary deteriorates materially.